The Food and Drug Administration has approved an Alzheimer's drug that appears to modestly slow down the disease. (Story aired on Weekend Edition Saturday on Jan. 6, 2023.)
The Food and Drug Administration has approved an Alzheimer's drug that appears to modestly slow down the disease.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
U.S. FDA approves Alzheimer's drug that appears to slow rate of cognitive declineThe drug, to be sold under the brand Leqembi, belongs to a class of treatments that aims to slow advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain.
Read more »
FDA Approves New Alzheimer's Drug Designed to Slow Cognitive DeclineThe US Food and Drug Administration (FDA) on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.
Read more »
EXPLAINER: New drug slows Alzheimer's but comes with caveatsA new Alzheimer’s drug is hitting the market with experts voicing a lot of caution
Read more »
New Alzheimer’s Drug Leqembi Will Be Out of Reach for Most PatientsA government rule limiting access to Alzheimer’s drugs means most patients who would want newly approved Leqembi won’t be able to get it—unless the Medicare agency rewrites the rule
Read more »
New Alzheimer's drug: What to know as Leqembi hits the marketHere are some things to know about the FDA's approval of lecanemab, to be sold under the brand name Leqembi.
Read more »